Analysts Expect Becton, Dickinson and Company (NYSE:BDX) Will Post Earnings of $2.83 Per Share

Equities research analysts expect that Becton, Dickinson and Company (NYSE:BDX) will announce earnings of $2.83 per share for the current quarter, according to Zacks Investment Research. Seven analysts have issued estimates for Becton, Dickinson and’s earnings, with the highest EPS estimate coming in at $2.97 and the lowest estimate coming in at $2.59. Becton, Dickinson and posted earnings per share of $4.55 during the same quarter last year, which suggests a negative year-over-year growth rate of 37.8%. The business is expected to announce its next quarterly earnings results on Thursday, February 3rd.

According to Zacks, analysts expect that Becton, Dickinson and will report full-year earnings of $12.41 per share for the current year, with EPS estimates ranging from $12.35 to $12.46. For the next year, analysts forecast that the company will report earnings of $13.64 per share, with EPS estimates ranging from $13.43 to $13.89. Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that cover Becton, Dickinson and.

Becton, Dickinson and (NYSE:BDX) last released its earnings results on Thursday, November 4th. The medical instruments supplier reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.45 by $0.14. Becton, Dickinson and had a net margin of 10.22% and a return on equity of 15.97%. The company had revenue of $5.10 billion for the quarter, compared to the consensus estimate of $4.91 billion. During the same quarter in the previous year, the firm earned $2.79 EPS. Becton, Dickinson and’s revenue was up 6.6% compared to the same quarter last year.

BDX has been the topic of several research reports. JPMorgan Chase & Co. cut shares of Becton, Dickinson and from an “overweight” rating to a “neutral” rating and reduced their price target for the stock from $276.93 to $265.00 in a research report on Friday, August 6th. SVB Leerink reissued a “market perform” rating on shares of Becton, Dickinson and in a research note on Friday, October 22nd. Finally, Zacks Investment Research upgraded Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $250.00 price target for the company in a report on Tuesday, October 19th. Five investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $271.00.

In other Becton, Dickinson and news, Director Rebecca W. Rimel sold 244 shares of the company’s stock in a transaction dated Thursday, September 2nd. The stock was sold at an average price of $254.00, for a total value of $61,976.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Rebecca W. Rimel sold 207 shares of the stock in a transaction dated Monday, August 30th. The shares were sold at an average price of $252.00, for a total value of $52,164.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 8,174 shares of company stock valued at $2,104,313. 0.76% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Keel Point LLC acquired a new stake in Becton, Dickinson and in the 2nd quarter valued at approximately $414,000. Viridian Ria LLC acquired a new stake in Becton, Dickinson and in the 3rd quarter valued at approximately $25,000. Focused Wealth Management Inc grew its holdings in Becton, Dickinson and by 101.7% in the 3rd quarter. Focused Wealth Management Inc now owns 100 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 6,000 shares during the last quarter. Meridian Wealth Partners LLC bought a new stake in shares of Becton, Dickinson and in the 1st quarter worth approximately $28,000. Finally, Mascoma Wealth Management LLC bought a new stake in shares of Becton, Dickinson and in the 3rd quarter worth approximately $34,000. 84.25% of the stock is currently owned by hedge funds and other institutional investors.

NYSE:BDX traded down $2.12 during trading hours on Thursday, reaching $244.46. 911,617 shares of the company were exchanged, compared to its average volume of 1,358,593. Becton, Dickinson and has a twelve month low of $226.15 and a twelve month high of $267.37. The firm has a market cap of $70.21 billion, a PE ratio of 35.69, a price-to-earnings-growth ratio of 2.73 and a beta of 0.70. The stock’s 50-day moving average is $246.23 and its 200-day moving average is $246.88. The company has a current ratio of 1.33, a quick ratio of 0.90 and a debt-to-equity ratio of 0.72.

Becton, Dickinson and announced that its Board of Directors has approved a stock repurchase plan on Thursday, November 4th that authorizes the company to buyback 10,000,000 shares. This buyback authorization authorizes the medical instruments supplier to repurchase shares of its stock through open market purchases. Shares buyback plans are usually an indication that the company’s leadership believes its stock is undervalued.

The business also recently announced a quarterly dividend, which will be paid on Friday, December 31st. Stockholders of record on Friday, December 10th will be issued a dividend of $0.87 per share. This represents a $3.48 annualized dividend and a dividend yield of 1.42%. This is an increase from Becton, Dickinson and’s previous quarterly dividend of $0.83. The ex-dividend date of this dividend is Thursday, December 9th. Becton, Dickinson and’s dividend payout ratio is currently 48.47%.

About Becton, Dickinson and

Becton, Dickinson & Co is a medical technology company. The firm engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public.

Featured Article: Stop Order Uses For Individual Investors

Get a free copy of the Zacks research report on Becton, Dickinson and (BDX)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with's FREE daily email newsletter.